MeSH tree: C23.550.835.900.356
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell ...
2 hours ago
0
0
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and mount potent anti-tumor responses. These properties make them an attractive candidate for next-generation ...
Apr 30, 2026
0
47
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own immune arsenal to fight ...
Mar 19, 2026
0
7
The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed after two or more prior ...
Dec 15, 2025
0
8
The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The ...
Dec 8, 2025
0
12
An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding interleukin 12 strategy that lets CAR-T cells treat prostate cancer in mice while curbing previously ...
Research led by Friedrich-Alexander-Universität Erlangen–Nürnberg provides evidence that teclistamab may offer therapeutic benefit for patients with severe forms of treatment-resistant autoimmune diseases.
New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) and published simultaneously in The Lancet shows that a much lower dose than previously ...
Sep 18, 2025
0
19
From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in children with high-risk metastatic, ...
Clinical data demonstrate the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small ...
Sep 8, 2025
0
37
